Cycle Pharmaceuticals Gains FDA Nod for Nilotinib Disintegrating Tablets, Expanding CML Treatment Options
Event summary
- Cycle Pharmaceuticals' CAVHANZA (nilotinib) Orally Disintegrating Tablets received FDA approval on June 2, 2026.
- The formulation improves solubility and dissolution rate, allowing co-administration with PPIs and H2RAs without timing restrictions.
- CAVHANZA is indicated for newly diagnosed and resistant Ph+ CML patients, addressing a 25% co-prescription challenge in the market.
- Cycle partnered with Flex Pharma, leveraging its ElectroNanoSpray™ platform for the advanced formulation.
- This marks Cycle's 10th product and 2nd offering for Ph+ CML patients.
The big picture
Cycle Pharmaceuticals' FDA approval for CAVHANZA underscores the growing trend of reformulating established oncology drugs to enhance bioavailability and patient compliance. The partnership with Flex Pharma highlights a strategic shift toward leveraging advanced formulation technologies to address unmet needs in rare disease treatment. This approval positions Cycle as a key player in the Ph+ CML space, with potential to expand its portfolio in other oncology indications.
What we're watching
- Market Penetration
- How Cycle will position CAVHANZA against existing nilotinib treatments and capture the 25% of CML patients co-prescribed acid-reducing agents.
- Commercial Execution
- Whether Cycle's patient support program, Cycle Vita, can drive adoption among newly diagnosed and resistant Ph+ CML patients.
- Pipeline Expansion
- The pace at which Cycle and Flex Pharma will collaborate on additional oncology formulations using the ElectroNanoSpray™ platform.
Related topics